BioStar files for rapid influenza test:
This article was originally published in Clinica
US firm BioStar has filed a 510(k) application with the FDA to market a rapid diagnostic for influenza which detects two types of the virus (A and B) simultaneously. Developed with Australian firm Biota Holdings, the test takes around 15 minutes to perform and needs no instrumentation. Boulder, Colorado-based BioStar said sales will be limited until the launch of Biota's anti-flu drug Relenza.
You may also be interested in...
Last year, Mallinckrodt attempted restructuring the firm to evade bankruptcy fears. However, the company is now filing for bankruptcy for its US generics business to address “unmanageable liabilities.”
Informa Pharma Intelligence has officially launched the seventh Global Generics & Biosimilars Awards, which will take place in October 2020 in Milan, Italy.
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.